Open AccessHaploidenticalvscord blood transplantation for adults with acute myelogenous leukemia
Author(s) -
Melhem Solh
Publication year - 2014
Publication title -
world journal of stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.907
H-Index - 18
ISSN - 1948-0210
DOI - 10.4252/wjsc.v6.i4.371
Subject(s) - medicine , transplantation , umbilical cord , leukemia , stem cell , sibling , cord blood , acute leukemia , cyclophosphamide , immunology , oncology , intensive care medicine , chemotherapy , biology , psychology , developmental psychology , genetics
Hematopoeitic cell transplantation is established as a curative treatment for patients w acute myelogenous leukemia. Haploidentical family donor and umbilical cord blood (UCB) are alternative sources of stem cells for patients lacking a matched sibling or unrelated donor. The early challenges of transplant complications related to poor engraftment and graft-vs-host disease have been overcome with new strategies such as using 2 units and increased cell dose in UCB and T-cell depletion and post transplantation cyclophosphamide in haploidentical transplantation. The outcomes of alternative transplantation for acute leukemia were compared to other traditional graft sources. For patients lacking a matched sibling or unrelated donor, either strategy is a suitable option. The choice should rely mostly on the urgency of the transplantation and the available cell dose as well as the expertise available at the transplant center. This manuscript reviews the options of alternative donor transplantation and highlights recent advances in each of these promising transplantation options.